{"nctId":"NCT00461305","briefTitle":"Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea","startDateStruct":{"date":"2007-02"},"conditions":["Dysmenorrhea"],"count":420,"armGroups":[{"label":"DRSP 3 mg/EE 20 µg (13 cycles)","type":"EXPERIMENTAL","interventionNames":["Drug: DRSP 3 mg/EE 20 µg (13 cycles)"]},{"label":"DRSP 3 mg/EE 30 µg (6 cycles)","type":"EXPERIMENTAL","interventionNames":["Drug: DRSP 3 mg/EE 30 µg (6 cycles)"]}],"interventions":[{"name":"DRSP 3 mg/EE 20 µg (13 cycles)","otherNames":[]},{"name":"DRSP 3 mg/EE 30 µg (6 cycles)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged 20 years or older at obtaining informed consent\n* Patients having the normal menstrual cycle (25 to 38 days) in the latest two menses before the final enrollment\n* Patients having a total dysmenorrheal score of at least 3 points in twice of the latest menstruation before the final enrollment\n\nExclusion Criteria:\n\n* Patients with ovarian chocolate cysts\n* Patients with fibroid needed to be treated\n* Patients with estrogen-dependent tumors and patients with cervical cancer or suspected cervical cancer\n* Patients with undiagnosed abnormal vaginal bleeding\n* Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease, or coronary artery disease or a history of those diseases\n* Patients aged 35 years or older who smoke at least 15 cigarettes per day\n* Patients with migraine accompanied by prodromata\n* Patients with pulmonary hypertension or valvular heart disease\n* Patients who are regularly taking nutritional products that contain St. John's Wort\n* Patients who underwent surgical treatment for endometriosis within 2 months prior to screening\n* Patients who may need to regularly use analgesics for therapeutic objectives other than relief from the pain of dysmenorrhea during this study (occasional use permitted)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Intracyclic Bleeding at Cycle 6","description":"Intracyclic bleedings were defined as bleedings while a participant takes active tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Total Dysmenorrhea Score at Cycle 6","description":"Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Total Dysmenorrhea Score at Cycle 13","description":"Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6","description":"Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13","description":"Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Lumbago During Menstruation at Cycle 6","description":"Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Lumbago During Menstruation at Cycle 13","description":"Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Headache During Menstruation at Cycle 6","description":"Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Headache During Menstruation at Cycle 13","description":"Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6","description":"Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13","description":"Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6","description":"Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13","description":"Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6","description":"VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.2","spread":null},{"groupId":"OG001","value":"-31.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13","description":"VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6","description":"VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13","description":"VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Any Bleeding Episodes From Cycle 1 to Cycle 6","description":"Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Any Bleeding Episodes From Cycle 1 to Cycle 13","description":"Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Any Bleeding Days From Cycle 1 to Cycle 6","description":"Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null},{"groupId":"OG001","value":"19.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Any Bleeding Days From Cycle 1 to Cycle 13","description":"Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 4 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6","description":"Intracyclic bleedings were defined as bleedings while a participant takes active tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13","description":"Intracyclic bleedings were defined as bleedings while a participant takes active tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6","description":"Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"276","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"302","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13","description":"Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"314","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"295","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6","description":"Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null},{"groupId":"OG001","value":"89.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13","description":"Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6","description":"Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null},{"groupId":"OG001","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"92.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"88.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13","description":"Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6","description":"CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.33","spread":null},{"groupId":"OG001","value":"-5.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum CA-125 From Baseline to Cycle 13","description":"CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6","description":"CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.159","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum CRP From Baseline to Cycle 13","description":"CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":null}]}]}]},{"type":"POST_HOC","title":"Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 6","description":"Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.68"},{"groupId":"OG001","value":"-2.2","spread":"1.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"1.52"},{"groupId":"OG001","value":"-2.1","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.58"},{"groupId":"OG001","value":"-2.3","spread":"1.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.61"},{"groupId":"OG001","value":"-2.0","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.64"},{"groupId":"OG001","value":"-2.3","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.45"},{"groupId":"OG001","value":"-1.3","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.61"},{"groupId":"OG001","value":"-2.0","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.54"},{"groupId":"OG001","value":"-2.4","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.61"},{"groupId":"OG001","value":"-2.1","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"1.67"},{"groupId":"OG001","value":"-2.1","spread":"1.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.71"},{"groupId":"OG001","value":"-2.4","spread":"1.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"1.37"},{"groupId":"OG001","value":"-1.9","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"1.73"},{"groupId":"OG001","value":"-2.6","spread":"2.04"}]}]}]},{"type":"POST_HOC","title":"Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 13","description":"Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"1.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"1.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"1.75"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":355},"commonTop":["Headache","Nasopharyngitis","Nausea","Dysmenorrhoea","Genital haemorrhage"]}}}